Nemocnica Na Okraji Mesta N.O.

The oncology department at Nemocnica Na Okraji Mesta N.O. is actively evaluating new treatment options for a range of solid tumours, including non‑small cell lung cancer, melanoma with BRAF V600E/K mutations, and hormone‑responsive breast cancers. Researchers are comparing innovative immunotherapy combinations with standard chemotherapy to determine if they can improve response rates and survival outcomes.

• Comparative studies of novel checkpoint inhibitor biosimilars in advanced lung cancer
• Combination of targeted agents and immunotherapy for BRAF‑mutated melanoma
• Evaluation of antibody‑drug conjugates for triple‑negative breast cancer
• Assessment of hormonal therapy plus CDK4/6 inhibition in estrogen‑receptor positive breast cancer
• Investigation of first‑line immunotherapy regimens in non‑squamous lung cancer

Across eight clinical trials, six investigators are working to bring more effective therapies to patients in Partizanske, Slovakia, reflecting the site’s commitment to advancing cancer care.

In addition to tumour‑directed studies, the centre is dedicated to addressing metabolic complications such as cancer cachexia that often accompany advanced disease. Trials focus on agents that may restore body weight and improve quality of life for patients with colorectal cancer and other malignancies experiencing severe weight loss.

• Anti‑GDF‑15 antibody therapy to increase body weight in cachectic cancer patients
• Oral metabolic modulators aimed at improving appetite in colorectal cancer with cachexia
• Safety and efficacy evaluation of novel agents targeting muscle wasting pathways
• Placebo‑controlled studies measuring weight change and functional outcomes
• Exploratory biomarkers of metabolic health in patients with advanced tumours

These eight trials, supported by a multidisciplinary team, highlight the site’s integrated approach to treating both the tumour and its systemic effects, offering hope for better overall patient wellbeing.